Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

NCT05814666 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis was negative

Conditions

HNSCC

Interventions

DRUG: Danvatirsen
DRUG: Pembrolizumab

Sponsor

Flamingo Therapeutics NV